Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults.
Edward E WalshGonzalo Pérez MarcAgnieszka M ZarebaAnn R FalseyQin JiangMichael PattonFernando P PolackConrado LlapurPablo A DoreskiKumar IlangovanMika RämetYasushi FukushimaNazreen HussenLouis J BontJose CardonaElliot DeHaanGiselle Castillo VillaMarinela IngilizovaDaniel EirasTarek MikatiRupal N ShahKatherine SchneiderDavid CooperKenneth KouryMaria-Maddalena LinoAnnaliesa S AndersonKathrin U JansenKena A SwansonAlejandra GurtmanWilliam C GruberBeate Schmoele-Thomanull nullPublished in: The New England journal of medicine (2023)
RSVpreF vaccine prevented RSV-associated lower respiratory tract illness and RSV-associated acute respiratory illness in adults (≥60 years of age), without evident safety concerns. (Funded by Pfizer; RENOIR ClinicalTrials.gov number, NCT05035212; EudraCT number, 2021-003693-31.).